Status:
COMPLETED
Mechanisms of Retinal Revascularization and Clinical Indicators of Neovascular AMD Relapse
Lead Sponsor:
Sorlandet Hospital HF
Conditions:
Wet Macular Degeneration
Eligibility:
All Genders
18+ years
Brief Summary
Age-related macular degeneration (AMD) is a chronic and progressive eye disease and is one of the leading causes of vision impairment globally. AMD is referred to as either the dry or the wet type, wh...
Eligibility Criteria
Inclusion
- Patients have to be 18 years or older
- Newly diagnosed nAMD (group 1) or nAMD treatment for at least 1 year (group 2), both with typical neovascular findings on OCT-A
- Patients with acceptable travel distance to the hospital
- Patients accepting to be part of the study
Exclusion
- Other non-AMD macular disorders
- A spherical equivalent of -6 diopters or less
- Opacities of the visual axis; Changes of the cornea, anterior chamber, lens or vitreous cavity causing image acquisition artefacts
- Patients not able to attend extra controls due to age, illnesses or other factors
- Contraindications of intraocular injection therapy; Active ocular or periocular infection, active and serious intraocular inflammation, hypersensitivity to the drug or recent stroke / heart attack
Key Trial Info
Start Date :
February 8 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 21 2024
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT05211804
Start Date
February 8 2022
End Date
May 21 2024
Last Update
June 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sorlandet Hospital HF
Arendal, Agder, Norway, 4838